Treatment for alcohol and opioid use disorders (AOUD) is feasible in primary care settings, but ongoing funding to support organizational capacity is critical for sustaining such programs.
The dopamine D3 receptor antagonist VK4-116 reduced oxycodone self-administration in rats, as well as drug-seeking behaviors after oxycodone reinstatement following withdrawal. VK4-116 did not interfere with oxycodone’s pain-relieving effects
In animal studies, α2δ-1 and its interactions with NMDA receptors in the spinal cord triggered the pain sensitivity and analgesic tolerance that occurs with chronic morphine treatment. Blocking the α2δ-1–NMDA interaction reduced opioid-induced hyperalgesia and analgesic tolerance.
The spread of marijuana use and the opioid epidemic over the past 10 years have affected middle-aged and older Americans. In addition, prescription opioid and benzodiazepine misuse increased older adults’ risk of suicidal thoughts.
Interim treatment with buprenorphine significantly improved the psychiatric symptoms of people awaiting comprehensive treatment for opioid use disorder (OUD). Buprenorphine treatment, even without concurrent psychosocial counseling, may help patients with no, or delayed, access to comprehensive OUD treatment.
A recent NIDA-sponsored study found higher rates of NAS among males than among females. A second study found that, among infants whose mothers were treated with buprenorphine while pregnant, NAS was more severe among those whose mothers used other substances.
Mindfulness-Oriented Recovery Enhancement (MORE) reduces opioid misuse among chronic pain patients. MORE shifts patients' attention away from drug cues and toward cues for natural rewards.
Several effective medications are now available for treating opioid use disorder but many patients who could benefit do not receive them. Some patients who receive the medications face challenges to staying in treatment.